The impact of this correlation is significant, as it indicates that TGase 2 can be a specific target for ccRCC therapy and that inhibitors such as GK921 and streptonigrin, which inhibit binding between TGase 2 and p53, can be an anti-cancer therapeutics [23,64]. The gene discussed is TGM2; the disease is nonpapillary renal cell carcinoma.